RGNX - Earnings announcements

Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026Robust patient enrollment continues in confirmatory trialSurabgene lomparvovec (sura-vec, ABBV-RGX-314) subretinal wet AMD topline pivotal data expected in Q4 2026; first patient dosed in pivotal Phase IIb/III trial in diabetic retinopathy expected in Q2 2026Company to engage FDA on potential path forward for RGX-121Conference call today at 8:00 a.m. ETROCKVILLE, Md., March 5, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today reported financial results and operational highlights f

ROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology comp

RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026Pivotal trial enrollment completed in October; confirmatory trial open and enrolling New 12-month analysis shows all participants demonstrate improved functional outcomes across multiple natural history methods of measurement, when decline is expectedClemidsogene lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; PDUFA date February 8, 2026Surabgene lomparvovec (sura-vec, ABBV-RGX-314) on track to be first gene therapy for chronic retinal diseaseEnrollment completed in pivotal trials evaluating subretinal delivery of sura

ROCKVILLE, Md., Oct. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, November 6, at 8:00 a.m. ET to discuss its financial results for the third quarter ended September 30, 2025, and operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a

RGX-202 in Duchenne muscular dystrophy on track for topline results 1H 2026 and BLA submission mid-2026Pivotal trial enrollment accelerated, expected to complete in October 2025 ahead of previous guidanceClemidsogene lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; FDA inspections completed successfullyPre-license inspection (PLI) of in-house manufacturing facility, quality systems and processes completed with no observationsBioresearch monitoring information (BIMO) inspection of laboratory and clinical data practices completed with no observationsSurabgene lomparvovec (sura-vec, ABBV-RGX-314) on track to be first gene therapy in chronic retinal dise

ROCKVILLE, Md., July 31, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, August 7, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2025, and operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) and enter the passcode 9571992. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to

RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026Pivotal trial more than half enrolled, with completion expected in 2025 Additional Phase I/II functional data expected 1H 2025 Initiating commercial supply manufacturing in Q3 2025FDA acceptance of Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121, partnered with Nippon Shinyaku) expected in May 2025 Pivotal data evaluating the safety and efficacy of the subretinal delivery of surabgene lomparvovec (ABBV-RGX-314, partnered with AbbVie) in patients with wet age-related macular degeneration are expected in 2026 and planning of diabetic retinopathy pivotal study continuesConference call today at 4

ROCKVILLE, Md., April 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mi

ROCKVILLE, Md., Feb. 26, 2025 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2024, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a leading

ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Wednesday, November 6, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-s

ROCKVILLE, Md., July 25, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2024, and recent operational highlights. To access the live call by phone, dial (646) 307-1963 (domestic) or (800) 715-9871 (international) and enter the passcode 4849384. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call. Those who plan on participating are advised to join 15 minutes prior

ROCKVILLE, Md., May 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-stage

New three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression Patient aged 12 years at dosing had expression level at 75.7% of controlEarly evidence of strength and motor function improvement observedOn track to initiate pivotal trial in second half of 2024 Webcast this morning, Tuesday, March 5, 8:30 a.m. ET, with principal investigatorROCKVILLE, Md., March 5, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today reported additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne muscular dystrophy (Duchenne) ages 4 to11 years old, including RGX-202 microdystrophin expression from

Focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value generationPrioritized pipeline is expected to further progress to pivotal stage and first BLA filing in 2024New updates planned for Duchenne and in-office delivery retinal disease programs starting in March$314 million in cash, cash equivalents and marketable securities as of December 31, 2023, expected to fund operational runway into the second half of 2025Conference call Tuesday, February 27, at 4:30 p.m. ETROCKVILLE, Md., Feb. 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced financial results for the fourth quarter and full year ended December 31, 2023, and r

ROCKVILLE, Md., Feb. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Tuesday, February 27, 2024, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2023, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. About REGENXBIO Inc. REGENXBIO is

Results support BLA submission in 2024 using the accelerated approval pathwayPrimary endpoint of patients achieving reduction in CSF biomarker of MPS II disease was met with statistical significance (p value of 0.00016) Patients treated with RGX-121 have showed continued improvement in neurodevelopmental skill acquisition up to four years and discontinued intravenous enzyme therapyCompany plans to discuss these results as part of a full rare disease program update on its conference call today, Wednesday, February 7, 4:30 p.m. ETROCKVILLE, Md., Feb. 7, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced topline results from the Phase I/II/III CAMPSIITE® trial of RGX-121 for the

Completed enrollment in cohort 2 of the Phase I/II AFFINITY DUCHENNE® trial of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophinNew three-month assessment in third patient at dose level 1 demonstrates largest increase in microdystrophin expression Patient aged 6.6 years old had expression level at 83.4% of controlOn track to initiate pivotal trial in second half of 2024 Company plans to discuss these new results as part of a full rare disease program update on its conference call today, Wednesday, February 7, 4:30 p.m. ETROCKVILLE, Md., Feb. 7, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today an

Pivotal topline results from the CAMPSIITE® trial of RGX-121 for the treatment of MPS II to be presentedConference call Wednesday, February 7, 4:30 p.m. ETROCKVILLE, Md., Jan. 31, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced presentations on its program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the 20th Annual WORLDSymposium™ 2024, taking place in San Diego, CA February 3-9, 2024. The presentations include the topline results from the pivotal phase of the Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of MPS II. The oral presentations will be presented as follows: Abstract Title: CAMPSIITE®

A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to the treatment burden of chronic anti-VEGF injections ABBV-RGX-314 continues to be well tolerated in over 100 patients from three dose levels with no drug-related serious adverse eventsABBV-RGX-314 in over 50 patients at third dose level demonstrated highest reduction in treatment burden:80% reduction in annualized injection rate50% injection-freeZero cases of intraocular inflammation observed in patients that received short-course prophylactic topical steroid ey

ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will present data from the Phase II AAVIATE® trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) at Hawaiian Eye and Retina 2024 Meeting being held January 13-19, 2024 in Maui, HI. ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet AMD, diabetic retinopathy and other additional chronic retinal conditions. Title: Suprachoroidal delivery of investigational ABBV-RGX-314 for neovascular AMD: Results from the Phase II AAVIATE® studyPresenter: John D. Pitcher, III, M.D., Eye

RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin, continues to be well-tolerated in three patients from dose level 1 (1x1014 GC/kg)Initial biomarker data in two patients who completed three-month assessment demonstrate robust microdystrophin expression with localization to the muscle cell membrane Patient aged 4.4 years old had expression level at 38.8% of controlTrial dose escalation expected by end of 2023Pivotal dose determination and initiation of pivotal program anticipated in 2024Plan to use RGX-202 microdystrophin as a surrogate endpoint to support a Biologics License Application filing using t

ROCKVILLE, Md., Sept. 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced presentations at the 28th Annual Congress of the World Muscle Society, taking place in Charleston, SC from October 3-7, 2023. Presentations include interim data from the Phase I/II AFFINITY DUCHENNE™ trial, including longer-term safety and initial microdystrophin protein expression levels in muscle at three months. The presentations will be presented as follows: Abstract Title: An investigational AAV8 gene therapy coding for a novel microdystrophin as a treatment for Duchenne muscular dystrophy (P16)Presenter: Jahannaz Dastgir, DO, Senior Director, Clinical Development, REGENXBIO Abstract Title: RGX-2

Continued progress on '5x'25' strategy to advance five AAV Therapeutics from REGENXBIO's internal pipeline and licensed programs into pivotal-stage or commercial products by 2025ABBV-RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVieInterim results from Phase II AAVIATE® and ALTITUDE® trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of intraocular inflammationAdditional interim efficacy data from the Phase II AAVIATE and ALTITUDE trials expected at upcoming medical conferences in second half 2023 and first half 2024Interim data from Phase II Bridging Study evaluating subreti

ROCKVILLE, Md., July 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Wednesday, August 2, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2023, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. About REGENXBIO Inc. REGENXBIO is a leading clinical-stage bi

Continued progress on '5x'25' strategy to advance five AAV Therapeutics from REGENXBIO's internal pipeline and licensed programs into pivotal-stage or commercial products by 2025Announced Updates to Eye Care Collaboration with AbbVieInvestigational gene therapy renamed ABBV-RGX-314IND sponsorship recently transferred to AbbVie for all ongoing clinical trialsExpanding sites and enrollment in ATMOSPHERE® and ASCENT™ pivotal trials using subretinal delivery; now expected to support U.S. and European regulatory submissions in late 2025 through the first half of 2026Completed enrollment in expansion cohorts in both Phase II AAVIATE® and ALTITUDE® trials of ABBV-RGX-314 using in-office suprachoroi

ROCKVILLE, Md., April 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Wednesday, May 3, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. About REGENXBIO Inc. REGENXBIO is a leading clinical-stage bio

Continued progress on '5x'25' strategy to advance five AAV Therapeutics from REGENXBIO's internal pipeline and licensed programs into pivotal-stage or commercial products by 2025RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVieEnrollment ongoing in the pivotal ATMOSPHERE® and ASCENT™ clinical trials using subretinal delivery, expected to support BLA filing in 2024Recently announced interim data from the Phase II pharmacodynamic study supports use of NAVXpress™ platform process in future commercialization plansRecently announced cohort expansions in AAVIATE® and ALTITUDE® suprachoroidal clinical trials on track to be completed

ROCKVILLE, Md., Feb. 21, 2023 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Tuesday, February 28, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2022, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. About REGENXBIO Inc. REGENXBIO is a leadin

Continued progress on 5x25 strategy to advance five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in 2024 Enrollment ongoing in the pivotal ATMOSPHERE® and ASCENT™ clinical trials of RGX-314 for the treatment of wet AMD using subretinal deliveryPresented positive interim data from RGX-314 trials for the treatment of wet AMD - the Phase II AAVIATE® trial using suprachoroidal delivery and the Phase I/IIa Long-term Follow-up study using subretinal delivery Announced expansio

ROCKVILLE, Md., Oct. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will present data from the ALTITUDE® clinical trial evaluating RGX-314 using suprachoroidal delivery for the treatment of patients with diabetic retinopathy at the Retina Society 55th Annual Scientific Meeting taking place in Pasadena, CA, from November 2-5, 2022. The Company will host a conference call on Thursday, November 3, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022, recent operational highlights and this interim data. Data Presentation Details: Title: Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy: The Phase II ALTITUDE Stud

Company announced positive interim data from and the expansion of Phase II AAVIATE® trial of RGX-314 for the treatment of wet AMD using suprachoroidal delivery RGX-314 continues to be well tolerated in 85 patients from Cohorts 1-5 with no drug-related serious adverse eventsMeaningful reduction in treatment burden at six months across all dose levels, 85% reduction in treatment burden observed at third dose level67% of patients in Cohort 4 were injection-freeNo meaningful differences in outcomes at six months for patients who are NAb positivePhase II trial expanded to include new cohort at third dose level with short-course prophylactic ocular steroids following RGX-314 administrationPositive

Company to host conference call on Monday, October 3rd at 8:30 a.m. ET to discuss new, interim data from the ongoing Phase II AAVIATE® trial ROCKVILLE, Md., Sept. 26, 2022 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30-October 3, 2022 in Chicago, IL. The presentations will highlight new and encore data for RGX-314, an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degeneration, diabetic retinopathy and other additional chronic retinal conditions. Presentations include: Title: Subretinal RGX-3

RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in 2024 Enrollment ongoing in the pivotal ATMOSPHERE® and ASCENT™ clinical trials of RGX-314 for the treatment of wet AMD using subretinal deliveryCompleted enrollment in Cohort 5 of the AAVIATE® trial of RGX-314 for the treatment of wet AMD using suprachoroidal deliveryCompleted enrollment in ALTITUDE® trial of RGX-314 for the treatment of diabetic retinopathy using suprachoroidal delivery AFFINITY DUCHENNE™ Phase I/II trial of RGX-202 remains on track for dosing in the first half of 2023 Announced intention to file a BLA in 2024 using th

ROCKVILLE, Md., Aug. 1, 2022 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Wednesday, August 3, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2022, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on particpating are advised to join 15 minutes prior to the start time. About REGENXBIO Inc.REGENXBIO is a leading clinical-stage biote

ROCKVILLE, Md., May 4, 2022 /PRNewswire/ -- Continues to advance RGX-314 program for the treatment of wet AMD and diabetic retinopathy; remains on track for first BLA filing in 2024 Enrollment ongoing in the pivotal ATMOSPHERE™ and ASCENT™ clinical trials of RGX-314 for the treatment of wet AMD using subretinal deliveryEnrollment ongoing in AAVIATE® trial of RGX-314 for the treatment of wet AMD using suprachoroidal deliveryEnrollment complete in ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy using suprachoroidal delivery Today announced update on initiation of AFFINITY DUCHENNE™ trial of RGX-202 for the treatment of DuchenneContinues plans for expanded enrollment of RGX

ROCKVILLE, Md., April 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Wednesday, May 4, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2022, and recent operational highlights. To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 5581898. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call. About REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology co

ROCKVILLE, Md., Feb. 22, 2022 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Tuesday, March 1, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2021, and recent operational highlights. To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 7635958. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call. About REGENXBIO Inc.REGENXBIO is a leading clinical-stage b

ROCKVILLE, Md., Oct. 26, 2021 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Tuesday, November 2, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2021, and recent operational highlights. To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 7878814. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call. About REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnol

ROCKVILLE, Md., Sept. 27, 2021 /PRNewswire/ -- Interim data for Cohort 1 with six months of follow-up from the RGX-314 Phase II trial for the treatment of wet AMD (AAVIATE®) to be presented REGENXBIO to host conference call and webcast to review the interim data from the AAVIATE trial on Friday, October 1, 2021, at 5:00 p.m. ET featuring wet AMD Key Opinion Leaders, Nikolas London, M.D., and Peter Campochiaro, M.D. REGENXBIO Inc. (NASDAQ:RGNX) today announced that data from the RGX-314 clinical trials will be presented in two oral presentations at the Retina Society 54th Annual Scientific Meeting taking place in Chicago, IL, from September 29 to October 2, 2021. RGX-314 is a potential best-i

NORTH CHICAGO, Ill. and ROCKVILLE, Md., Sept. 13, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) and REGENXBIO Inc. (NASDAQ:RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.  Under the collaboration, REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbV

ROCKVILLE, Md., Aug. 2, 2021 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Monday, August 9, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2021, and recent operational highlights. To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 8655773. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call. About REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology compa